Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (231-240 of 471) with videos related to

Pageof 48
Sort By:
European Journal of Heart Failure|May 22, 2012
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)David Preiss, Dirk J van Veldhuisen, Naveed Sattar, et al.
European Journal of Heart Failure|January 27, 2009
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programLarry A Allen, G Michael Felker, Stuart Pocock, et al.
Circulation|October 18, 2012
Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillatorRobert W Rho, Kristen K Patton, Jeanne E Poole, et al.
European Journal of Heart Failure|September 18, 2021
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALESSu E Yeoh, Pooja Dewan, Matteo Serenelli, et al.
JAMA|March 27, 2007
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome TrialMarvin A Konstam, Mihai Gheorghiade, John C Burnett, et al.
European Heart Journal|May 24, 2006
The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMETMichel Komajda, Stefan D Anker, Andrew Charlesworth, et al.
The American Journal of Cardiology|January 9, 2016
Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial)Thomas D Cook, Stephen J Greene, Andreas P Kalogeropoulos, et al.
Revista Espanola De Cardiologia|April 26, 2005
[Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]Markku S Nieminen, Michael Böhm, Martin R Cowie, et al.
European Journal of Heart Failure|February 24, 2012
Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trialAndrew P Ambrosy, Muthiah Vaduganathan, Mark D Huffman, et al.
European Journal of Heart Failure|November 2, 2010
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarctionJens Jakob Thune, James E Signorovitch, Lars Kober, et al.
Pageof 48

Showing results (231-240 of 471) with videos related to

Sort By:
Pageof 48
European Journal of Heart Failure|May 22, 2012
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)David Preiss, Dirk J van Veldhuisen, Naveed Sattar, et al.
European Journal of Heart Failure|January 27, 2009
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programLarry A Allen, G Michael Felker, Stuart Pocock, et al.
Circulation|October 18, 2012
Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillatorRobert W Rho, Kristen K Patton, Jeanne E Poole, et al.
European Journal of Heart Failure|September 18, 2021
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALESSu E Yeoh, Pooja Dewan, Matteo Serenelli, et al.
JAMA|March 27, 2007
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome TrialMarvin A Konstam, Mihai Gheorghiade, John C Burnett, et al.
European Heart Journal|May 24, 2006
The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMETMichel Komajda, Stefan D Anker, Andrew Charlesworth, et al.
The American Journal of Cardiology|January 9, 2016
Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial)Thomas D Cook, Stephen J Greene, Andreas P Kalogeropoulos, et al.
Revista Espanola De Cardiologia|April 26, 2005
[Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]Markku S Nieminen, Michael Böhm, Martin R Cowie, et al.
European Journal of Heart Failure|February 24, 2012
Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trialAndrew P Ambrosy, Muthiah Vaduganathan, Mark D Huffman, et al.
European Journal of Heart Failure|November 2, 2010
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarctionJens Jakob Thune, James E Signorovitch, Lars Kober, et al.
Pageof 48